Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

  • The 12 Biotechs of Christmas: Six

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

  • The 12 Biotechs of Christmas: Five

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

  • The 12 Biotechs of Christmas: Four

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

  • The Twelve Biotechs of Christmas: Two

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

  • Such A Pleasant Stay

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

  • Sea of Tranquility

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

  • Tropic of Palatin

    [Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

  • Ten Common Biotech Investing Mistakes

    [Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]

  • Quickster: T2 Biosystems ($TTOO)

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page to see his biography, latest comments and past articles.] About 18 months ago, I came across tiny Boston-area diagnostics start-up […]

  • The State of Things: Ruction at Regulus

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]

  • Conflict Diamonds

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]

  • Recent Author Comments

    On The Rest of the 12 Biotechs of Christmas
    One of our Gummune, Tim Fris, is facing an incredibly difficult time with a medical crisis in a family member. He has hard weeks ahead of him. I think it is extremely important that this community support him during this time. It could literally happen to [...]
    On The Rest of the 12 Biotechs of Christmas
    Thanks for mentioning this one, which I've been peeking in on now and again for months. I've never mentioned the company here because I wanted to see evidence in animal models that they can do what they are setting out to do. Which is this: instead of gene[...]
    On The Rest of the 12 Biotechs of Christmas
    Trade notification to the Gummune: Hold on to something. A former perma-bull for $CELG, I have exited the stock. My reasons: (1) ozanimod success baked in at present prices (2) I have a dim view of the executive suite falderal that's just happened (3)[...]
    On The Rest of the 12 Biotechs of Christmas
    Traydon: in my view, the number one thing to keep an eye on here is competitive landscape. Look at Ardelyx, and its lead agent. I predict that agent WILL be approved for both indications, including hyperphosphatemia. And that this will quite adversely affe[...]
    On The Rest of the 12 Biotechs of Christmas
    Non-biotech investing: Lin-ling: $NVDA is a mo-mo stock that has slowed, slipped transiently from favor. Do you think now is a good time to load up? Personal long $NVDA with 2/3 weight position.[...]
    On The Rest of the 12 Biotechs of Christmas
    Honor Roll post and thank you, lumpy. I think it is fascinating when members give us a detailed snapshot of what they are doing and why. I think this gives other readers material into which to sink their teeth. I like your picks and your distribution of th[...]
    On The Rest of the 12 Biotechs of Christmas
    John: you've never sounded stupid. Hush! In my view, no sincere comment or question is ever stupid, and even if it's not the most intellectually resounding thing ever to emerge from your brain, we all have wobbly days now and again, me included.[...]
    On The Rest of the 12 Biotechs of Christmas
    Hi all.....I am not absent, but my presence here may be spotty the next few days. I am initiating a long planned house move and it's not a small undertaking. It's not so much that the houses in question are grandiose or that I'm loaded with possessions----[...]
    On The Twelve Biotechs of Christmas: One
    Thanks. Ja, $AXSM is really misbehaving. Tempted to dump it until a bottom is CLEARLY in. It is NOT a junk stock, but certainly has bad manners right now. Long $AXSM, $TGTX, $SCYX, $CUR.[...]
    On The Rest of the 12 Biotechs of Christmas
    Thanks bigger. Extremely useful to know.[...]
    On The Twelve Biotechs of Christmas: One
    Thanks Scorpio for noting that for sicilia. I would add someone was commenting yesterday that of our recent long ideas, about a quarter have blown up, another quarter been static, and half done well. We adjust the "picking" algorithm and have tuned it to b[...]
    On The Rest of the 12 Biotechs of Christmas
    Agree with's geoff's points about $AUPH. Today's descent unsurprising. May add. Long $AUPH and overweight.[...]
    On The Rest of the 12 Biotechs of Christmas
    Hi diplacus....glad you are using your noggin'. I'm not sure the rule works for diagnostics companies, as it was intended for biopharma, and diagnostics players because of the nature of that game sometimes lack the same degree of institutional buying, at l[...]
    On The Rest of the 12 Biotechs of Christmas
    Effect size: how washing hands prevented death from childbirth related sepsis in 19th century Vienna, as quantified by Ignaz Semmelweis: https://pbs.twimg.com/media/C5LWWaBUEAEetWe.jpg Because of this discover, Semmelweis was fired for being "disrupt[...]
    On The Rest of the 12 Biotechs of Christmas
    Sorry Paul....wasn't trying to steal your thunder. This is the same data Kaly gave at Noblecon but with some amplification and granularity. It's got a couple of dings from patients having ID complications utterly unrelated to cannabidiol, but I can tell yo[...]
    On The Rest of the 12 Biotechs of Christmas
    News release from today pertinent to Kalytera situation (h/t Odi Bruckman, Tel Aviv) http://finance.yahoo.com/news/kalytera-therapeutics-announces-encouraging-results-141902756.html No position yet in Kalytera.[...]
    On The Rest of the 12 Biotechs of Christmas
    Lumpified: It's baaaad. Their raison d'etre, the centerpiece of their future, is gone with a capital G. No point in them having built a ginormous plant nearby now.[...]
    On The Rest of the 12 Biotechs of Christmas
    The Argos $ARGS debacle is final proof, as if proof necessary, that winning a Nobel Prize in science forever thereafter undermines the soundness of your cognition. (No position in $FLKS either.....).[...]
    On The Rest of the 12 Biotechs of Christmas
    Out at $AGEN when market opens. Time to move on, people. It's not going to be bought and cannot wield its magical Chilean shrub adjuvant to any meaningful effect.[...]
    On The Rest of the 12 Biotechs of Christmas
    Thanks Sogiam. Definitely NOT what we've been expecting, given actions and overtures of the company, but it underscores how deeply flawed the "tumor vaccine" concept is. Gotta be honest: there's not a reason any more, in my view, to be in this one. W[...]

    This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.